TABLE 4.
Variables | N = 156 |
---|---|
Conversion therapy (Yes/No) | 17/139 |
Conversion rate | 10.9% (17/156) |
Surgery | 5 |
RFA | 3 |
TACE | 3 |
Atez/Bev discontinuation | 6 |
Curative therapy (Surgery or RFA) | 47.1% (8/17) |
Non‐curative therapy | 52.9% (9/17) |
Abbreviations: Atez/Bev, atezolizumab plus Bevacizumab; RFA, radiofrequency ablation; TACE: transarterial chemoembolization.